United States - English - NLM (National Library of Medicine)

mayne pharma inc. - norgestimate (unii: c291hfx4dy) (norgestimate - unii:c291hfx4dy), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - nymyo tablets are indicated for use by females of reproductive potential to prevent pregnancy [see clinical studies ( 14)] . do not prescribe nymyo to women who are known to have the following conditions: - a high risk of arterial or venous thrombotic diseases. examples include women who are known to: smoke, if over age 35[ see boxed warning and warnings and precautions (5.1)] have deep vein thrombosis or pulmonary embolism, now or in the past[see warnings and precautions (5.1)] have inherited or acquired hypercoagulopathies[see warnings and precautions (5.1)] have cerebrovascular disease[see warnings and precautions (5.1)] have coronary artery disease[see warnings and precautions (5.1)] have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation)[see warnings and precautions (5.1)] have uncontrolled hypertension[see warnings and precautions (5.4)] have diabetes mellitus with vascular disease

United States - English - NLM (National Library of Medicine)

a-s medication solutions - norgestimate (unii: c291hfx4dy) (norgestimate - unii:c291hfx4dy), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - mili tablets are indicated for use by females of reproductive potential to prevent pregnancy [see clinical studies (14)] . do not prescribe mili to women who are known to have the following conditions: - a high risk of arterial or venous thrombotic diseases. examples include women who are known to: smoke, if over age 35 [see boxed warning and warnings and precautions (5.1)] have deep vein thrombosis or pulmonary embolism, now or in the past [see warnings and precautions (5.1)] have inherited or acquired hypercoagulopathies [see warnings and precautions (5.1)] have cerebrovascular disease [see warnings and precautions (5.1)] have coronary artery disease [see  warnings and precautions (5.1)] have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) [see warnings and precautions (5.1)] have uncontrolled hypertension [see warnings and precautions (5.4)] have diabetes mellitus with vascu

United States - English - NLM (National Library of Medicine)

rpk pharmaceuticals, inc. - norgestimate (unii: c291hfx4dy) (norgestimate - unii:c291hfx4dy), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - vylibra tablets are indicated for use by females of reproductive potential to prevent pregnancy [see clinical studies (14)] . vylibra is contraindicated in females who are known to have or develop the following conditions: - a high risk of arterial or venous thrombotic diseases. examples include women who are known to: smoke, if over age 35 [see boxed warning and warnings and precautions (5.1)] have deep vein thrombosis or pulmonary embolism, now or in the past [see warnings and precautions (5.1)] have inherited or acquired hypercoagulopathies [see warnings and precautions (5.1)] have cerebrovascular disease [see warnings and precautions (5.1)] have coronary artery disease [see  warnings and precautions (5.1)] have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) [see warnings and precautions (5.1)] have uncontrolled hypertension [see warnings and precautions (5.4)] have diabet

United States - English - NLM (National Library of Medicine)

a-s medication solutions - norgestimate (unii: c291hfx4dy) (norgestimate - unii:c291hfx4dy), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - tri femynor tablets are indicated for use by females of reproductive potential to prevent pregnancy [see clinical studies (14) ]. tri femynor is indicated for the treatment of moderate acne vulgaris in females at least 15 years of age, who have no known contraindications to oral contraceptive therapy and have achieved menarche. tri femynor should be used for the treatment of acne only if the patient desires an oral contraceptive for birth control [see clinical studies (14) ]. do not prescribe tri femynor to women who are known to have the following conditions: - a high risk of arterial or venous thrombotic diseases. examples include women who are known to: - smoke, if over age 35 [see boxed warning and warnings and precautions (5.1) ] - have deep vein thrombosis or pulmonary embolism, now or in the past [see warnings and precautions (5.1) ] - have inherited or acquired hypercoagulopathies [see warnings and precautions (5.1) ] - have cerebrovascular disease [see warnings and precautions (5.1) ] - have coronary

United States - English - NLM (National Library of Medicine)

a-s medication solutions - norgestimate (unii: c291hfx4dy) (norgestimate - unii:c291hfx4dy), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - tri femynor tablets are indicated for use by females of reproductive potential to prevent pregnancy [see clinical studies (14) ]. tri femynor is indicated for the treatment of moderate acne vulgaris in females at least 15 years of age, who have no known contraindications to oral contraceptive therapy and have achieved menarche. tri femynor should be used for the treatment of acne only if the patient desires an oral contraceptive for birth control [see clinical studies (14) ]. do not prescribe tri femynor to women who are known to have the following conditions: - a high risk of arterial or venous thrombotic diseases. examples include women who are known to: - smoke, if over age 35 [see boxed warning and warnings and precautions (5.1) ] - have deep vein thrombosis or pulmonary embolism, now or in the past [see warnings and precautions (5.1) ] - have inherited or acquired hypercoagulopathies [see warnings and precautions (5.1) ] - have cerebrovascular disease [see warnings and precautions (5.1) ] - have coronary

United States - English - NLM (National Library of Medicine)

central texas community health centers - norgestimate (unii: c291hfx4dy) (norgestimate - unii:c291hfx4dy), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - mononessa and trinessa tablets are indicated for use by females of reproductive potential to prevent pregnancy [see clinical studies (14)] . trinessa is indicated for the treatment of moderate acne vulgaris in females at least 15 years of age, who have no known contraindications to oral contraceptive therapy and have achieved menarche. trinessa should be used for the treatment of acne only if the patient desires an oral contraceptive for birth control [see clinical studies (14)] . do not prescribe mononessa or trinessa to women who are known to have the following conditions: - a high risk of arterial or venous thrombotic diseases. examples include women who are known to: smoke, if over age 35 [see boxed warning and warnings and precautions (5.1)] have deep vein thrombosis or pulmonary embolism, now or in the past [see warnings and precautions (5.1)] have inherited or acquired hypercoagulopathies [see warnings and precautions (5.1)] have cerebrovascular disease [see warnings and precautions (5.1)] have

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals inc, - norgestimate (unii: c291hfx4dy) (norgestimate - unii:c291hfx4dy), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - mononessa and trinessa tablets are indicated for use by females of reproductive potential to prevent pregnancy [see clinical studies (14)] . trinessa is indicated for the treatment of moderate acne vulgaris in females at least 15 years of age, who have no known contraindications to oral contraceptive therapy and have achieved menarche. trinessa should be used for the treatment of acne only if the patient desires an oral contraceptive for birth control [see clinical studies (14)] . do not prescribe mononessa or trinessa to women who are known to have the following conditions: there is little or no increased risk of birth defects in women who inadvertently use cocs during early pregnancy. epidemiologic studies and meta-analyses have not found an increased risk of genital or non-genital birth defects (including cardiac anomalies and limb reduction defects) following exposure to low dose cocs prior to conception or during early pregnancy. do not administer cocs to induce withdrawal bleeding as a test for pregnanc

United States - English - NLM (National Library of Medicine)

rpk pharmaceuticals, inc. - norgestimate (unii: c291hfx4dy) (norgestimate - unii:c291hfx4dy), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - tri-vylibra tablets are indicated for use by females of reproductive potential to prevent pregnancy [see clinical studies (14)] . tri-vylibra is indicated for the treatment of moderate acne vulgaris in females at least 15 years of age, who have no known contraindications to oral contraceptive therapy and have achieved menarche. tri-vylibra should be used for the treatment of acne only if the patient desires an oral contraceptive for birth control [see clinical studies (14)] . tri-vylibra is contraindicated in females who are known to have or develop the following conditions: - a high risk of arterial or venous thrombotic diseases. examples include women who are known to: smoke, if over age 35 [see boxed warning and warnings and precautions (5.1)] have deep vein thrombosis or pulmonary embolism, now or in the past [see warnings and precautions (5.1)] have inherited or acquired hypercoagulopathies [see warnings and precautions (5.1)] have cerebrovascular disease [see warnings and precautions (5.1)]

United States - English - NLM (National Library of Medicine)

proficient rx lp - ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u), norgestimate (unii: c291hfx4dy) (norgestimate - unii:c291hfx4dy) - ethinyl estradiol 0.025 mg - tri-lo-marzia™ tablets are indicated for use by females of reproductive potential to prevent pregnancy [see clinical studies (14)]. do not prescribe tri-lo-marzia to women who are known to have the following conditions:    o  smoke, if over age 35 [see boxed warning and warnings and precautions (5.1)]    o  have deep vein thrombosis or pulmonary embolism, now or in the past [see warnings and precautions (5.1)]    o  have inherited or acquired hypercoagulopathies [see warnings and precautions (5.1)]    o  have cerebrovascular disease [see warnings and precautions (5.1)]    o  have coronary artery disease [see warnings and precautions (5.1)]    o  have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) [see warnings and precautions (5.1)]    o  have uncontrolled hypertension [see warnings and precautions (5.3)]    o  have diabetes mellitus with vascular disease [see warnings and precautions (5.5)]    o  

United States - English - NLM (National Library of Medicine)

lupin limited - ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u), norgestimate (unii: c291hfx4dy) (norgestimate - unii:c291hfx4dy) - ethinyl estradiol 0.025 mg - tri-lo-marzia™ tablets are indicated for use by females of reproductive potential to prevent pregnancy [see clinical studies (14)]. do not prescribe tri-lo-marzia to women who are known to have the following conditions: - a high risk of arterial or venous thrombotic diseases. examples include women who are known to:    o  smoke, if over age 35 [see boxed warning and warnings and precautions (5.1)]    o  have deep vein thrombosis or pulmonary embolism, now or in the past [see warnings and precautions (5.1)]    o  have inherited or acquired hypercoagulopathies [see warnings and precautions (5.1)]    o  have cerebrovascular disease [see warnings and precautions (5.1)]    o  have coronary artery disease [see warnings and precautions (5.1)]    o  have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) [see warnings and precautions (5.1)]    o  have uncontrolled hypertension [see warnings and precaution